Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00314249 · ClinicalTrials.gov registry record · Phase 3

Study of Milnacipran for the Treatment of Fibromyalgia

A Phase 3 study of Fibromyalgia, sponsored by Forest Laboratories.

Completed
Registry status
Phase 3
Development phase
1,025
Enrollment target
20
Study locations

NCT00314249 is a Phase 3 study of Fibromyalgia that has completed, run by Forest Laboratories. The registered enrollment target is 1,025 participants, above the 166-participant average among 76 other Fibromyalgia trials with a reported enrollment target (517% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00314249, a Phase 3 study of Fibromyalgia, has completed, sponsored by Forest Laboratories.

COMPLETED
Registry status
Phase 3
Development phase
1,025 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

Conditions Studied

Fibromyalgia

Interventions

  • DRUG Placebo
  • DRUG Milnacipran 100mg

Study Locations (20)

California

  • Forest Investigative Site - Fresno
  • Forest Investigative Site - Pismo Beach
  • Forest Investigative Site - Vista

Florida

  • Forest Investigative Site - St. Petersburg
  • Forest Investigative Site - St. Petersburg
  • Forest Investigative Site - Stuart

Ohio

  • Forest Investigative Site - Cleveland
  • Forest Investigative Site - Columbus
  • Forest Investigative Site - Toledo

Massachusetts

  • Forest Investigative Site - Springfield
  • Forest Investigative Site - Worcester

New York

  • Forest Investigative Site - Johnson City
  • Forest Investigative Site - Syracuse

Alabama

  • Forest Investigative Site - Tuscaloosa

Georgia

  • Forest Investigative Site - Atlanta

Nebraska

  • Forest Investigative Site - Omaha

Trial Details

FieldValue
Enrollment Target 1,025 participants
Start Date 2006-04
Phase Phase 3

Sponsor

Forest Laboratories

145 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00314249

The ClinicalTrials.gov registry entry for NCT00314249 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,025 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 166-participant average among 76 other Fibromyalgia trials with a reported enrollment target (517% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00314249 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT00314249 about?

NCT00314249 is a clinical study titled "Study of Milnacipran for the Treatment of Fibromyalgia". The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.

What is the current status of trial NCT00314249?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,025 participants. The study started on 2006-04.

What conditions does trial NCT00314249 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT00314249?

The interventions under investigation include: Placebo (DRUG), Milnacipran 100mg (DRUG).

Who is sponsoring clinical trial NCT00314249?

This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00314249 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Fibromyalgia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.